Newsmax Pharmaceuticals Inc. today announced a new general and SEG600-series drug development product against SARS-CoV-2 the virus that causes COVID-19 disease. Newsmax expects to seek FDA authorization following the FDAs Thursday announcement of its intent to provide greater information on the SARS-CoV-2-specific neutralization assay drug. The company expects to launch the new product at two units one in Omaha Nebraska and one in Duncan Virginia.

The Dow Coronavirus SARS-CoV-2-specific neutralization assay is best known for being used in drug development for drug candidates against tobacco and alcohol. The drug candidate is being evaluated as a potential antiviral treatment for COVID-19 and is also being tested as a potential platform for other diseases. Newsmax expects to reveal regulatory information on the drug candidates safety and efficacy potential on December 1 2020.

About Newsmax Pharmaceuticals Inc.

Newsmax is a biopharmaceutical company focused on developing antibody and antibody-drug candidates against novel coronaviruses with a focus on CUREV-19. As a leading biopharmaceutical company through its CUREV-19 program Newsmax expects to development novel antibody and antibody-drug candidates antigens that have demonstrated efficacy for use in clinical trials and clinical trials of investigational novel antiretroviral and small molecule inhibitors. Newsmax is also developing inhibitors of the key RNA and protein products of SARS-CoV-2. Newsmax intends to broaden its portfolio of global drug candidates for COVID-19 to more relevant compounds. In addition Newsmax is developing an antibody-drug candidate against SARS-CoV-2 using two different antigens tested in its COVID-19 viral vector drug candidate. Newsmax expects to submit its intent to the U. S. Food and Drug Administration (FDA) for approval prior to the end of 2018.

Newsmax completed its IPO process on the Nasdaq Market Capitalization under the symbol Nex. The IPO raised 3 billion in financing and the company anticipates additional funding of 1. 8 billion in its IPO prospectus.

CMV Pathfinder has been acquired by Newsmax as part of the Nasdaq-backed transaction.